153 related articles for article (PubMed ID: 38750474)
21. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive analysis of TPX2-related ceRNA network as prognostic biomarkers in lung adenocarcinoma.
Huo C; Zhang MY; Li R; Zhou XJ; Liu TT; Li JP; Liu X; Qu YQ
Int J Med Sci; 2020; 17(16):2427-2439. PubMed ID: 33029085
[No Abstract] [Full Text] [Related]
23. LINC00467 Is Upregulated by DNA Copy Number Amplification and Hypomethylation and Shows ceRNA Potential in Lung Adenocarcinoma.
Wang W; Bo H; Liang Y; Li G
Front Endocrinol (Lausanne); 2021; 12():802463. PubMed ID: 35095769
[TBL] [Abstract][Full Text] [Related]
24. Immune- and Stemness-Related Genes Revealed by Comprehensive Analysis and Validation for Cancer Immunity and Prognosis and Its Nomogram in Lung Adenocarcinoma.
Chen M; Wang X; Wang W; Gui X; Li Z
Front Immunol; 2022; 13():829057. PubMed ID: 35833114
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive analysis of prognostic biomarkers in lung adenocarcinoma based on aberrant lncRNA-miRNA-mRNA networks and Cox regression models.
Yao Y; Zhang T; Qi L; Liu R; Liu G; Wang J; Song Q; Sun C
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31950990
[TBL] [Abstract][Full Text] [Related]
26. Methylation and transcriptome analysis reveal lung adenocarcinoma-specific diagnostic biomarkers.
Li R; Yang YE; Yin YH; Zhang MY; Li H; Qu YQ
J Transl Med; 2019 Sep; 17(1):324. PubMed ID: 31558162
[TBL] [Abstract][Full Text] [Related]
27. Multiomics analysis on DNA methylation and the expression of both messenger RNA and microRNA in lung adenocarcinoma.
Yang Z; Liu B; Lin T; Zhang Y; Zhang L; Wang M
J Cell Physiol; 2019 May; 234(5):7579-7586. PubMed ID: 30370535
[TBL] [Abstract][Full Text] [Related]
28. Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD.
Ma C; Gu Z; Yang Y
J Cell Mol Med; 2024 Apr; 28(8):e18282. PubMed ID: 38647237
[TBL] [Abstract][Full Text] [Related]
29. Multi-omics immune regulatory mechanisms in lung adenocarcinoma metastasis and survival time.
Liu D; Yao L; Ding X; Zhou H
Comput Biol Med; 2023 Sep; 164():107333. PubMed ID: 37586202
[TBL] [Abstract][Full Text] [Related]
30. A Novel Predictive Model Incorporating Ferroptosis-Related Gene Signatures for Overall Survival in Patients with Lung Adenocarcinoma.
Wang Y; Pan Y; Wu J; Luo Y; Fang Z; Xu R; Teng W; Chen M; Li Y
Med Sci Monit; 2022 Feb; 28():e934050. PubMed ID: 35102130
[TBL] [Abstract][Full Text] [Related]
31. Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis.
Bi G; Chen Z; Yang X; Liang J; Hu Z; Bian Y; Sui Q; Li R; Zhan C; Fan H
Cancer Immunol Immunother; 2020 Jul; 69(7):1293-1305. PubMed ID: 32189030
[TBL] [Abstract][Full Text] [Related]
32. STARD12/14 are diagnostic and prognostic biomarkers of lung adenocarcinoma associated with epigenetic regulation, immune infiltration and ferroptosis.
Zhang WD; Hu DM; Shi ZE; Wang QX; Zhang MY; Liu JY; Ji XL; Qu YQ
Int J Med Sci; 2023; 20(11):1427-1447. PubMed ID: 37790851
[No Abstract] [Full Text] [Related]
33. Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.
Zhai Y; Zhao B; Wang Y; Li L; Li J; Li X; Chang L; Chen Q; Liao Z
BMC Cancer; 2021 Mar; 21(1):213. PubMed ID: 33648465
[TBL] [Abstract][Full Text] [Related]
34. Identifying the miRNA signature associated with survival time in patients with lung adenocarcinoma using miRNA expression profiles.
Yerukala Sathipati S; Ho SY
Sci Rep; 2017 Aug; 7(1):7507. PubMed ID: 28790336
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
[TBL] [Abstract][Full Text] [Related]
36. System analysis of
Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
[TBL] [Abstract][Full Text] [Related]
37. Screening of Methylation Gene Sites as Prognostic Signature in Lung Adenocarcinoma.
Dong M; Yang Z; Li X; Zhang Z; Yin A
Yonsei Med J; 2020 Dec; 61(12):1013-1023. PubMed ID: 33251775
[TBL] [Abstract][Full Text] [Related]
38. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
Front Immunol; 2021; 12():724741. PubMed ID: 34335635
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive analysis of the association between tumor-infiltrating immune cells and the prognosis of lung adenocarcinoma.
Pan Y; Sha Y; Wang H; Zhuang H; Ren X; Zhu X; Wei X
J Cancer Res Ther; 2020; 16(2):320-326. PubMed ID: 32474519
[TBL] [Abstract][Full Text] [Related]
40. Bulk RNA-seq and scRNA-seq reveal SLC7A11, a key regulatory molecule of ferroptosis, is a prognostic-related biomarker and highly related to the immune system in lung adenocarcinoma.
Wu X; Wang S; Chen K
Medicine (Baltimore); 2023 Sep; 102(37):e34876. PubMed ID: 37713821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
